Your browser doesn't support javascript.
loading
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Halperin, Scott A; Ye, Lingyun; MacKinnon-Cameron, Donna; Smith, Bruce; Cahn, Pedro E; Ruiz-Palacios, Guillermo M; Ikram, Aamer; Lanas, Fernando; Lourdes Guerrero, M; Muñoz Navarro, Sergio Raúl; Sued, Omar; Lioznov, Dmitry A; Dzutseva, Vitalina; Parveen, Ghazala; Zhu, Fengcai; Leppan, Laura; Langley, Joanne M; Barreto, Luis; Gou, Jinbo; Zhu, Tao.
  • Halperin SA; Canadian Center for Vaccinology, Dalhousie University, IWK Health, Nova Scotia Health, Halifax, Canada. Electronic address: scott.halperin@dal.ca.
  • Ye L; Canadian Center for Vaccinology, Dalhousie University, IWK Health, Nova Scotia Health, Halifax, Canada.
  • MacKinnon-Cameron D; Canadian Center for Vaccinology, Dalhousie University, IWK Health, Nova Scotia Health, Halifax, Canada.
  • Smith B; Canadian Center for Vaccinology, Dalhousie University, IWK Health, Nova Scotia Health, Halifax, Canada.
  • Cahn PE; Fundación Huésped, Buenos Aires, Argentina.
  • Ruiz-Palacios GM; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Ikram A; National Institute of Health, Islamabad, Pakistan.
  • Lanas F; Universidad de la Frontera, Temuco, Chile.
  • Lourdes Guerrero M; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Muñoz Navarro SR; Universidad de la Frontera, Temuco, Chile.
  • Sued O; Fundación Huésped, Buenos Aires, Argentina.
  • Lioznov DA; Federal State Budgetary Institution, Smorodintsev Research Institute of Influenza, St Petersburg, Russia.
  • Dzutseva V; Medical School, Novosibirsk State University, Novosibirsk, Russia.
  • Parveen G; National Institute of Health, Islamabad, Pakistan.
  • Zhu F; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
  • Leppan L; Canadian Center for Vaccinology, Dalhousie University, IWK Health, Nova Scotia Health, Halifax, Canada.
  • Langley JM; Canadian Center for Vaccinology, Dalhousie University, IWK Health, Nova Scotia Health, Halifax, Canada.
  • Barreto L; CanSino Biologics, Tianjin, China.
  • Gou J; CanSino Biologics, Tianjin, China.
  • Zhu T; CanSino Biologics, Tianjin, China.
Lancet ; 399(10321): 237-248, 2022 01 15.
Article en En | MEDLINE | ID: mdl-34953526
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article